Our understanding of the context for driver mutations in certain cancers and their association with chromatin functions influencing the cancer transcriptome is currently limited. Improvements will be essential to enable molecular insights into disease processes and to pioneer improved therapy concepts. We work closely with genetic/transgenetic clinical research (both human and animal) and with histo-pathology labs, both within Austria and international. Group members focus mainly on aberrant signal transduction and molecular mechanisms of cancer causing disease often involving transgenic animal models and patient sample analysis.

To top